Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1640MR)

This product GTTS-WQ1640MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1640MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14597MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ7623MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ4058MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ12439MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ7214MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7360MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ7132MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ9716MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW